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Abstract
Background: There is a consensus about the importance of ‘recovery’ in mental health services, but the evidence
base is limited.
Methods/Design: A two centre, cluster randomised controlled trial. Participants are community-based mental health
teams, and service users aged 18-65 years with a primary clinical diagnosis of psychosis. In relation to the REFOCUS
Manual researchintorecovery.com/refocus, which describes a 12-month, pro-recovery intervention based on the
REFOCUS Model, the objectives are: (1) To establish the effectiveness of the intervention described in the REFOCUS
Manual; (2) To validate the REFOCUS Model; (3) To establish and optimise trial parameters for the REFOCUS Manual;
and (4) To understand the relationship between clinical outcomes and recovery outcomes. The hypothesis for the
main study is that service users in the intervention arm will experience significantly greater increases in measures of
personal recovery (as measured by the QPR) compared to service users receiving care from control teams. The
hypothesis for the secondary study is that black service users in the intervention arm will experience significantly
greater increases in measures of personal recovery (as measured by the QPR) and client satisfaction (as measured by
the CSQ) compared to Black service users receiving care from control teams.
The intervention comprises treatment as usual plus two components: recovery-promoting relationships and working
practices. The control condition is treatment as usual. The primary outcme is the Process of Recovery Questionnaire
(QPR). Secondary outcomes are satisfaction, Goal setting - Personal Primary Outcome, hope, well-being, empowerment,
and quality of life. Primary outcomes for the secondary study will be QPR and satisfaction. Cost data will be estimated,
and clinical outcomes will also be reported (symptomatology, need, social disability, functioning).
29 teams (15 intervention and 14 control) will be randomised. Within each team, 15 services users will be randomly
chosen, giving a total sample of 435 service users (225 in intervention and 210 in control). Power for the main study: 336
service users will give power to detect a medium effect size of 0.4 (alpha 0.05, power = 0.8) on both QPR sub-scales.
Power for the secondary study: 89 participants will give power to detect an effect size of 0.67 on both QPR sub-scales
and on CSQ. A range of approaches are used to minimise bias, although service users and clinicians cannot be blinded.
Discussion: This cluster-RCT will evaluate a pro-recovery intervention in community mental health teams.
Trial registration: ISRCTN: ISRCTN02507940
1. Background
There is a policy and professional consensus about the
importance of ‘recovery’ in mental health services, defined
as “a way of living a satisfying, hopeful, and contributing
life” even with any limitations caused by illness [1-4]. This
has recently been elaborated: “Recovery is the process of
regaining active control over one’sl i f e .T h i sm a yi n v o l v e
discovering (or rediscovering) a positive sense of self,
accepting and coping with the reality of any ongoing dis-
tress or disability, finding meaning in one’s experience,
resolving personal, social or relationship issues that may
contribute to one’s mental health difficulties, taking on
satisfying and meaningful social roles and calling on for-
mal and/or informal systems of support as needed” [5].
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any medium, provided the original work is properly cited.The REFOCUS Study is a research programme funded
through the National Institute for Health Research Pro-
gramme Grants for Applied Research scheme (RP-PG-
0707-10040). The REFOCUS Trial is part of the REFOCUS
Study. The REFOCUS Trial is evaluating an intervention
(described in the REFOCUS manual [6]) based on the
REFOCUS Model, which is derived from wider research
[7] and specifically informed by a systematic review and
narrative synthesis of personal recovery [8]. The REFOCUS
Model is shown in Figure 1.
There is a robust evidence base, including several sys-
tematic reviews, for the key elements of the intervention,
including the contribution of coaching [9,10], values
[11,12], strengths [13,14] and goal-striving [15,16]. This is
the first intervention to evaluate their combined use in a
complex intervention in adult community mental health
services in the NHS in England. The intervention is based
on systematic reviews [8] and international best practice
[17], and informed by research into staff-service user rela-
tionships [18,19] and stigma [20]. Evaluation of the inter-
vention is particularly timely given the current emphasis
on recovery and the associated concept of well-being [21]
in English mental health services. The results of the trial
will be of relevance to (a) developing mental health policy
and associated clinical guidelines; (b) clinical practice.
The experiences of recovery of individuals from minority
ethnic backgrounds have been insufficiently researched, so
a secondary study is being conducted to examine trial out-
comes for participants from black backgrounds.
Understanding the relationship between clinical and
recovery outcomes is vital if debates about the future
direction of mental health services are to be informed by
evidence. These debates are happening [22], and the
empirical evidence base is very limited [23]. This study
will address this knowledge gap.
2. Methods/design
Objectives and hypotheses
The REFOCUS Trial has four objectives
Objective 1: To establish the effectiveness of the
intervention described in the REFOCUS manual,
using outcome evaluation to demonstrate that service
users receiving care from intervention teams make more
progress towards their personal recovery than those
receiving care from control teams. The primary outcome
measure (QPR) and the secondary outcome measures
are listed in Section 13. All outcomes pertain to the
individual level and include both staff and service user
outcomes.
Main study hypothesis: Service users in the interven-
tion arm will experience significantly greater increases
in measures of personal recovery (as measured by the
QPR) compared to service users receiving care from
control teams.
Secondary study hypothesis: Black service users in the
intervention arm will experience significantly greater
increases in measures of personal recovery (as measured
by the QPR) and client satisfaction (as measured by the
CSQ) compared to Black service users receiving care from
control teams.
Objective 2: To validate the REFOCUS Model,
using process evaluation to investigate the extent to
which the intended consequences of the intervention
are predicted by the REFOCUS Model.
Objective 3: To establish and optimise trial para-
meters for the REFOCUS Manual, including recruitment
and retention issues, fidelity, outcome and economic eva-
luation, implementation strategies, missing data analysis,
and sample size calculation
Objective 4: To understand the relationship
between clinical outcomes and recovery outcomes
comprising recovery outcomes of hope, empowerment,
well-being, quality of life and personal recovery, and clin-
ical outcomes of symptomatology, needs and social
disability.
Design
This is a two centre cluster-randomised controlled trial,
with paired teams randomised to receive the intervention
or standard care/treatment as usual arms of the trial. The
recovery intervention will be delivered by all members of
staff who provide a clinical input to the team.
The intervention will be provided to a complete team,
using implementation strategies to support individual
practitioners to introduce and maintain these changes. To
minimise contamination, the unit of randomisation and
analysis is the mental health team. To understand the
impact of the intervention a process evaluation will be
undertaken.
Ethics and trial registration
Ethical approval was obtained from East London REC 3
approval 11/LO/0083 on 22.2.11. The trial registration
number is ISRCTN02507940 http://www.controlled-trials.
com/isrctn.
Study setting
The intervention will be evaluated in two Mental Health
Trusts: South London and Maudsley NHS Foundation
Trust (SLaM) and
2gether Partnership NHS Foundation
Trust in Gloucestershire.
SLaM is the largest mental health Trust in the UK, has
an annual income of £330 m, spent across over 100 sites
spanning urban and suburban settings. It employs 4,500
staff in 296 teams, works with 34,128 service users, and
provide adult mental health services across four Boroughs
(Croydon, Lambeth, Lewisham, Southwark). These ser-
vices are provided through Clinical Academic Groups
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education and training for the benefit of patient care. Peo-
ple who use SLaM services are ethnically diverse, with
37% of people using SLaM services recorded on the
clinical information system as coming from a ‘Black Afri-
can’, ‘Black Caribbean’ or ‘Black other’ background.
2gether is a rural/semi-rural Trust, employing 806 staff
in 23 adult mental health teams, and working with 4,301
Figure 1 The REFOCUS Model.
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2gether services are ethni-
cally homogenous, with a very small number of black
individuals using services. Therefore the secondary study
will be conducted in SLaM only.
Sample
Team inclusion criteria
￿ Adult, community-based mental health team (due to
the diversity in in-patient provision [24,25])
￿ Any Complex Care or Promoting Recovery team in
the SLaM Psychosis Clinical Academic Group (CAG) or
any in
2gether
￿ Provide a care co-ordinating function
Service user inclusion criteria
￿ Aged 18-65 years
￿ Primary clinical diagnosis ofp s y c h o s i s ,e . g .s c h i z o -
phrenia, schizo-affective disorder, bipolar disorder
￿ No immediate plans for discharge or transfer
￿ Not currently receiving in-patient care or in prison
￿ Speaks and understands English
￿ Not participating in substantial other study
￿ Has participating paired staff
￿ In opinion of clinician, is sufficiently well to
participate
￿ In regular contact with at least one worker in the
team
Service user exclusion criteria
￿ Service users who are unable to give consent or are
too unwell to be interviewed (in the opinion of clinician)
￿ No participating paired staff
￿ Service user whereabouts unknown or service user is
uncontactable
Additional service user inclusion criteria for secondary
study
￿ From black African, black Caribbean, black British
or black other backgrounds
Staff inclusion criteria
￿ Provides clinical input into a team included in the
trial
￿ Does not also provide clinical input into a team allo-
cated to the opposite arm of the trial.
￿ In addition, paired staff completing staff-rated ser-
vice user measures are in regular clinical contact with
service users who are recruited into the trial.
Sample size
Main study
The primary outcome is the Process of Recovery Question-
n a i r e( Q P R )[ 2 6 ] .T h i sm e a s u r ew a sc h o s e na st h eo n l ys e r -
vice user-rated measure of personal recovery which has
been developed in England and with adequate psycho-
metric properties (described in Section 13.2). Since perso-
nal recovery is something experienced rather than assessed
by an expert, a self-report measure was appropriate for
clinical end-point. The timing between baseline and fol-
low-up (i.e. the length of the intervention) was chosen as
12 months to allow sufficient time for team-level changes
in practice to occur, be sustained, and have an impact.
The QPR has two sub-scales: intrapersonal (mean =
45.7, sd = 16.1, range 13-68) and interpersonal (mean =
14.0, sd = 3.7, 0-20). The sample size calculation is based
on being able to detect a medium standardised effect size
of 0.4 in both sub-scales, which equates to a difference of
6.4 points on the QPR intrapersonal subscale and 1.5
points on the interpersonal subscale.
The estimated sample size for a two-group comparison
of means (alpha = 0.05, power = 0.8) is 99 per group.
However, as this is a team-level intervention, the unit of
randomisation is the team. An initial 29 teams (20 from
SLaM, 9 from
2gether) will be recruited, and we anticipate
17% attrition (due to team mergers or restructuring), giv-
i n gat o t a lo f2 4t e a m s( 1 6f r o mS L a M ,8f r o m
2gether).
The same number of participants will be included from
each team. Adjustment for clustering within teams
assumes an intracluster correlation of 0.05, with equal
numbers of clusters in each randomisation group. For 24
teams, 164 participants are needed per group, i.e. 14 parti-
cipants per team. To allow for one participant (7%) drop-
out per team, 15 participants per team will be recruited
from the 29 teams. This drop-out rate is consistent with
attrition in previous randomised controlled trials we have
conducted [27].
The total initial sample is therefore 435 service users,
comprising 225 in intervention and 210 in control. Based
on the above attrition and clustering estimates, we antici-
pate this will produce an analysable sample of 336 parti-
cipants, giving power to detect a medium effect size of
0.4 (alpha 0.05, power = 0.8) on both QPR sub-scales.
Secondary study
In a pre-planned sub-group analysis, we will also be inves-
tigating the outcomes of service users from black back-
grounds in the SLAM site only. The primary outcomes for
this sub-study will be the QPR (as above) and the Client
Satisfaction Questionnaire - 8 item version (CSQ) [28],
which produces a global satisfaction score (mean = 24, sd
= 6) within this population. CSQ data were available from
a previous study [29], from which a retrospective analysis
of data from black individuals demonstrated an effect size
of 0.67 for differences in CSQ between intervention and
control groups. The sample size calculation for the sec-
ondary study is based on being able to detect a large effect
size of 0.67, equating to a difference of 10.8 on the QPR
intrapersonal subscale, 2.5 on the QPR interpersonal sub-
scale, and 4 on the CSQ.
Using the same estimates for a two-group comparison
of means as for the main study (20% SLaM team attri-
tion, 7% participant attrition, 0.05 intra-cluster correla-
tion, alpha 0.05, power 0.8), 6 participants per team will
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participants) is anticipated to produce an analysable
sample of 89 participants, giving power to detect an
effect size of 0.67 on both QPR sub-scales and on CSQ.
Recruitment and randomisation procedures
Teams will be recruited into the trial over a 12 month per-
iod, at a rate of 5-6 SLaM teams every three months and
4-5
2gether teams every five months. One of the aims of
this trial is to establish whether this planned recruitment
rate is feasible. The service user baseline assessment mea-
sures are anticipated to take up to 90 minutes, so if neces-
sary will be completed in two face to face meetings with
researchers. The generic staff baseline assessment will take
up to 20 minutes and the paired staff baseline assessment
measures will take an additional 20 minutes per service
user. They will either be completed at the community
base or within the service user’s own home, at a mutually
agreed time.
Participating teams will be randomly allocated on an
equal basis to intervention (N = 15) and control groups (N
= 14). Allocation will be stratified by site (six sites: four
SLaM Boroughs, two
2gether localities) to ensure balance.
Randomisation will be undertaken using processes set out
by the independent Mental Health and Neuroscience Clin-
ical Trials Unit, on the basis of a team identification num-
ber and site information. Service users will be allocated
based on these clusters.
The clinical information system will be accessed by
either Clinical Studies Officers (CSOs) from National
Institute for Health Research (NIHR) Mental Health
Research Network (MHRN), information analysts or the
researchers acting under arrangements with the responsi-
ble Trust to compile the list of names, diagnoses, ethni-
city and date of births for randomisation. This will be the
only access to clinical information by the research team
prior to consent.
In
2gether, a randomly ordered list of service users on
the caseload of each team with a clinical diagnosis of psy-
chosis will be generated using the same procedures as set
out by the Clinical Trials Unit. The first 15 service users
will be selected from the randomly ordered caseload list.
In SLaM, two randomly ordered lists of service users
with a psychosis diagnosis on the caseload of the team
will be generated using a random number table. One list
(List A) will comprise service users who come from ser-
vice users who are from black African, black Caribbean
and black other backgrounds, and the other list (List B)
will comprise all other service users. The first 6 service
u s e r sf r o ml i s tAa n dt h ef i r s t9f r o ml i s tBw i l lb e
selected, giving a total sample of 15 per SLaM team. This
will ensure epidemiological representativeness in the
sample in relation to black ethnicity, and will ensure suf-
ficient power to test the secondary study hypothesis.
If an individual does not meet inclusion criteria or
refuses consent to participate, then the next person from
the appropriate randomly-ordered list will be chosen.
Caseload randomisation will be undertaken using proce-
dures set out by the Mental Health and Neuroscience
Clinical Trials Unit, on the basis of a service user identifi-
cation number.
Approaches to minimise bias
Due to the nature of the intervention, neither clinicians
nor service users can be blinded to allocation status.
However, several approaches have been used to mini-
mise bias.
Addressing bias at allocation
1. All randomisation will be undertaken by the research
team following procedures set out by the independent
Clinical Trials Unit which has been awarded full CTU
registration by UKCRC. Identifying information about
teams or service users will not be known before
randomisation.
Addressing bias in baseline data
2. Baseline data from staff and service users will as far
as feasible be collected before allocation, to avoid bias
based on allocation status
Addressing bias in the intervention
3. The research team will monitor implementation
across sites, in order to maximise fidelity and ensure
comparability of the intervention between sites.
4. Change in staff for each team will be carefully moni-
tored, with particular attention paid to identifying staff
that move between teams in different allocation arms.
This will allow contamination to be estimated.
Addressing bias in follow-up data
5. All included services users will be followed up and
included in the analysis using intention-to-treat
approaches, reducing the impact of selective attrition.
6. At follow-up assessment, participants will be asked
not to reveal their allocation status, and at the end of the
interview the rater will record their guess about the service
user’s allocation status. This will allow researcher blind-
ness to be estimated.
7. Follow-up data will where possible be collected by
CSOs from the National Institute for Health Research
Mental Health Research Network (MHRN). This will
increase the likelihood of rater blindness.
8. Bias in the outcome data will be minimised by the
use of standardised objective assessments, and informed
by previous outcomes research [30,31].
9. Some evaluation data will be obtained from casenotes,
thus reducing the possibility of respondent bias. More
generally, the multi-method approach to evaluation
includes data collected from staff, service users, researcher
ratings, and case note audit. This reduces the impact of
bias in any individual data source.
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unblinding will be necessary as only intervention group
participants are involved, will be collected after the fol-
low-up outcome evaluation data.
11. Protected data storage with clear access protocols
in line with Good Clinical Practice Guidelines [32] will
be used to store allocation and outcome data separately.
Addressing bias in analysis
12. No data regarding the allocation status will be
stored in the data entry database
13. All data will be stored in either a locked filing
cabinet or in an electronic password-protected database.
14. The primary data analysis will be undertaken blind
to allocation status
15. Allocation status will coded as A and B in all data
requests.
Control
All participating teams provide care co-ordination for cli-
ents. The framework for care co-ordination and resource
allocation in mental health c a r ei st h eC a r eP r o g r a m m e
Approach (CPA) [33]. The CPA process is well-established
in the trial sites. Key components of this approach include:
￿ Systematic arrangements for assessing the health and
social needs of people accepted into specialist mental
health services
￿ The formation of a care plan which identifies the
health and social care required from a variety of
providers
￿ The appointment of a key worker to keep in close
t o u c hw i t ht h es e r v i c eu s e ra n dt om o n i t o ra n dc o - o r d i n a t e
care
￿ Regular review and, where necessary, agreed changes
to the care plan.
￿ Individuals will continue to receive treatment as
usual, directed by the principles and CPA process out-
lined above.
Individuals within the control teams will continue to
receive treatment as usual, as directed by the principles
and CPA process outlined above.
Intervention
The intervention comprises a 12-month, team-level pro-
recovery intervention in addition to standard care. It
includes recovery interventions to be carried out at both
the team (cluster) and individual practitioner level. The
intervention is described in detail in the REFOCUS
manual (available from http://researchintorecovery.com/
refocus). In summary, it involves two components:
A. Recovery-promoting relationships
￿ Training and reflection opportunities will be offered to
teams to allow them to understand what personal recov-
ery means in their context, to consider their own values
and how these can support recovery, and to develop and
practice the use of coaching skills.
￿ People who use services can be active agents in
shaping the content of clinical interactions. Service
users will be supported to develop expectations that
their values, strengths and goal-striving will be
prioritised.
￿ Partnership relationships recognise the professional
expertise of staff and the expertise from lived experience
of service users. Teams will undertake a project to develop
and practise partnership working, e.g. through staff and
service users doing or learning something jointly.
B. Pro-recovery working practices
￿ Understanding the service user’s values and treatment
preferences underpin an individualised approach to care
planning. Workers will be trained in understanding values.
￿ Amplifying a service users’ strengths and ability to acc-
cess community supports is an important approach to
supporting recovery. Workers will be trained in assessing
strengths.
￿ Identifying personally valued goals, developing inter-
mediate steps, and striving towards these goals contri-
butes to recovery. Workers will be trained to use
existing care planning skills to support goal-striving.
The practice change is supported by an implementation
strategy, described in detail in the REFOCUS manual. In
summary, the process involves six implementation compo-
nents: i) Information sharing; ii) Personal recovery train-
ing; iii) Coaching and working practice training; iv) Team
manager reflection groups; v) Team reflection sessions;
and vi) Supervision reflection.
Measures
Staff-Rated Measures
Generic ￿ The Sociodemographics Form - Worker (SF-
W) is a staff-rated form developed specifically for the
trial, which records the person’s age, gender, ethnicity,
languages spoken, qualifications, core profession, current
role, grade, team, time since qualification, personal
experience of mental illness, and experience of caring for
a family member or friend with a mental illness.
￿ The Recovery Knowledge Inventory (RKI) is a 20-
item staff-rated measure of staff knowledge and attitudes
about recovery [34].
￿ The Mental Illness: Clinicians’ Attitudes (MICA)
Scale is a 16-item of attitudes towards mental illness
(staff-rated) [35].
￿ The Recovery Fidelity Scale - Worker (RFS-W) is
a staff-rated measure developed specifically for the trial,
which assesses fidelity to the intervention elements.
￿ The Implementation Scale (RIS) is a staff-rated mea-
sure developed specifically for the trial, which assesses the
experience of the six implementation strategies.
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come Scale (HoNOS) is a 12-item staff-rated measure
of social disability [36].
￿ Camberwell Assessment of Needs Short Appraisal
Schedule-(CANSAS - S) is a 22-item staff-rated assess-
ment of health and social needs [37].
￿ The Global Assessment of Functioning (GAF) is a
3-item staff rated measure of impairment in functioning
due to physical (or environmental) limitations.
Service User-Rated Measures
Outcome measures ￿ (Primary outcome) The Process of
Recovery Questionnaire (QPR) is a 22-item service
user-rated assessment of personal recovery [26]. Each
item is rated on a five-point scale from 0 (Disagree
Strongly) to 4 (Agree strongly). Two subscale scores are
produced: Intrapersonal sub-scale based on 17 items
(range 0 to 4, high score good) and the Interpersonal
sub-scale based on 5 items (range 0 to 4, high score
good). The QPR was developed in the UK and has been
used with a population of people who have experienced
psychosis. It has an internal consistency of r = 0.94 for
the Intrapersonal sub-scale and r = 0.77 for the Interper-
sonal sub-scale, indicating good internal consistency. It
obtained good test-re-test reliability for both sub-scales
(Intrapersonal: r = 0.874, p = 0.001) and (Interpersonal:
r = 0.769, p = 0.001). It also has good construct validity
and correlates with the Making Decisions Empowerment
Scale, Schizophrenia Quality of Life Scale and General
Health Questionnaire.
￿ (Secondary outcome) The Warwick-Edinburgh
Mental Well-Being Scale (WEMWBS) is a 14-item
service user-rated of well-being [38].
￿ (Secondary outcome) The Mental Health Confi-
dence Scale (MHCS) is a 16-item service user-rated
measure of empowerment [39].
￿ (Secondary outcome) The Herth Hope Index (HHI)
is a 12-item service user-rated measure of client levels
of hope [40].
￿ (Secondary outcome) The Manchester Short
Assessment of Quality of Life (MANSA) is a 16-item
service-user rated measure of quality of life [41].
￿ (Secondary outcome) The Goal setting - Personal
Primary Outcome (GS-PPO) is a service user-rated mea-
sure developed specifically for this trial, which identifies a
personally-valued outcome as an alternative to the pre-
defined primary outcome of the trial.
￿ (Secondary outcome) Client Satisfaction Question-
naire (CSQ) is an 8-item service user-rated measure of cli-
ent satisfaction with mental health services [28].
￿ Camberwell Assessment of Needs Short Appraisal
Schedule-(CANSAS - SU) is a service user-rated 22-
items measure of health and social needs [37]. Both staff
and service user perspectives are assessed becase they
differ [42,43]
￿ ICECAP-A is service user-rated 5-item measure of
overall quality of life which intended for use in eco-
nomic evaluation [44].
Process measures 1. The Importance of services in
recovery (INSPIRE) is a service user-rated measure of
recovery orientation of services which was developed
specifically for this trial.
2. The Recovery Fidelity Scale - Service User (RFS-
SU) is a service user-rated measure developed specifically
for this trial, which assesses experience of the intervention
elements. Each item is rated on a five-point scale ranging
from 0 (Strongly Disagree) to 4 (Strongly Agree). The
Total score is calculated by summing each item and multi-
plying by 25. The total score ranges from 0 (low fidelity) to
100 (high fidelity).
Other measures 3. The Sociodemographics Form - Ser-
vice User (SF-SU) is a service user-rated form developed
specifically for the trial, which allows recording of the
service user’s date of birth, gender, ethnicity, languages
spoken, country of birth, education, employment, marital
status, and housing. It also records (in tear-off form for
separate filing) a range of contact details (e.g. mobile,
email, contact information for a relative) to facilitate con-
tact with service users who are no longer on the caseload
of the team at follow-up.
10. The National Adult Reading Test (NART) is a
measure of pre-morbid level of intellectual functioning
[45].
Researcher-Rated Measures
1. The Brief Psychiatric Rating Scale (BPRS) is an 18-
item observer-rated measure of symptomatology which is
completed with the service user [46].
2. The Client Service Receipt Inventory (CSRI) is a
tool for collecting cost-related information about people
with mental health problems for use in mental health
service evaluations [47].
Team-Manager/leader measures
1. The Team Characteristics Form (TC-F) is a team
manager/leader-rated form developed specifically for the
trial, which records the team’s key characteristics, such
as caseload size, composition, type of team and support
offered, and whether it has undergone any significant
changes within the last 12 months.
Trial procedures
Eligible teams will be recruited into the trial over a 12
month period, starting April 2011. Baseline data collec-
tion will start in teams four to five months prior to the
start of the intervention. All staff who meet inclusion cri-
teria in the participating teams will be asked to complete
the generic staff measures: SF-W, MICA, RFS-W and
RKI. Staff will identify whether each randomly identified
service user meets the eligibility criteria. Eligible service
users will then be approached by their Care Co-ordinator
Slade et al. BMC Psychiatry 2011, 11:185
http://www.biomedcentral.com/1471-244X/11/185
Page 7 of 13or another appropriate staff member from their team and
asked whether they are willing to be contacted by
researchers. If they agree to be contacted, then Clinical
Studies Officers or research workers will then approach
the potential participants, in liaison with staff. Potential
participants will be given a detailed explanation of the
study and a written Participant Information Sheet. If they
are willing to participate, they will be asked to sign a con-
sent form and complete the baseline interview, compris-
ing: QPR, WEMBWS, MANSA, GS-PPO, CSQ, RFS-SU,
I N S P I R E - T E A M ,N A R T ,M H C S ,H H I ,C A N S A S - S U ,
ICECAP-A, SF-SU, CSRI, and BPRS. If necessary, the
baseline assessment will be spread over more than one
meeting. Participants will be paid £10 for taking part and
entered into a raffle competition to win a £100 gift
voucher.
Following baseline assessment of the service user, their
care co-ordinator or other appropriate team member
will be asked to complete the three service user-specific
measures: HoNOS, CANSAS-S and GAF.
Four to five months (varying across sites) after baseline
data collection began, teams will be randomly allocated
with 50% likelihood into either the intervention or control
groups. The intention is that all baseline data will be col-
lected before allocation, but where this is not possible any
remaining baseline data will be collected post-allocation.
On completion of the baseline assessments, teams will be
given a £100 book voucher.
The 12-month intervention will be provided for inter-
vention group teams only. Attendance at all training
and reflection sessions will be recorded.
At the intervention mid-point (6 months) team leaders
in the intervention teams will be asked to complete the
RFS-W.
At the end of the intervention, all service users who
completed baseline assessments will be re-contacted in liai-
son with their care co-ordinator. Where the service user is
no longer in contact with the team, efforts will still be
made to contact them for a follow-up assessment. The
follow-up assessment will be conducted by the CSO
or research worker, and will comprise the following
m e a s u r e s :Q P R ,W E M B W S ,M A N S A ,G - S - P P O ,C S Q ,
RFS-SU, INSPIRE-TEAM, MHCS, HHI, CANSAS-SU,
ICECAP-A, SF-SU, CSRI, and BPRS. The interviewer will
guess allocation status at the end of the interview. If neces-
sary, the follow-up assessment will be spread over more
than one meeting. Participants will be paid £10 for taking
part and entered into a raffle competition to win a £100
gift voucher.
After the follow-up assessment of the service user,
their care co-ordinator or other appropriate team mem-
ber will be asked to complete the three service user-spe-
cific measures: HoNOS, CANSAS-S and GAF. They will
also identify the current primary clinical diagnosis. If
the baseline staff respondent is no longer working with
the service user, then the most appropriate member of
staff will be asked to complete the measures instead.
All staff in intervention group teams (whether paired
with service users or not) will be asked to rate RKI, MICA,
RFS-W and RIS. All staff in control group teams will be
asked to rate RKI, MICA and RFS-W. Any new staff in
either group will also complete SF-W. The trial is planned
to start in April 2011, with follow-up completed by
December 2013.
A summary of the assessment measures is shown in
Table 1.
Process evaluation
In addition to the baseline and follow-up data collected,
four process evaluation approaches will be used.
1. Longitudinal routine data
Longitudinal routine data will be collected from the clini-
cal information system at six-monthly intervals starting
one year before baseline and continuing until follow-up
(i.e. at baseline - 12 months, baseline - 6 months, baseline,
baseline + 6 months, baseline + 12 months, baseline + 18
months). At each recording point, anonymised data will be
collected from the care plans for the participating service
users. Each care plan entry will be rated for Topic and
Responsibility, using categories developed in a previous
study [48].
Topic categories comprise: Psychotropic medication;
Symptoms/Relapse prevention; Care Programme
Approach; Outpatient clinic; Physical health; Social needs;
Emotional Support; Functional/Activities of Daily Living;
Accommodation needs; Healthy Lifestyle; Financial;
Employment; Education; and Carer work/Support.
Responsibility categories identify who is responsible for
actions in the care plan, and comprise: Staff; Service user;
Staff and service user; Carer; Staff and Carer; Service user
and Carer; and Staff, service user and carer. Data will be
collected for each consenting service user participant.
Anonymised data will be collected from the three clin-
ical information system fields: Values and treatment pre-
ference; Strengths; and Personally valued goals.
2. Interviews
Staff participants in individual interviews and focus groups
will comprise intervention group (a) front-line community
mental health team staff that have direct clinical contact
with service users (b) team leaders/managers. Service user
participants in individual interviews and focus groups will
comprise people on the caseload of intervention group
teams. Trainer participants will comprise (a) Personal
Recovery trainers and (b) Coaching for recovery trainers.
Interviews with staff (N = 30) Interviews will be held
midway through the trial (6 months), with individual
members of staff from the intervention teams at both
sites (N = 15). The topic guide will explore the experience
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Page 8 of 13of participating in the trial, and identify implementation
influences.
At the end of the trial (12 months), interviews will be
held with individual members of staff from the interven-
tion teams, about their experience of taking part in the
study and in what ways (if any) their working practices
have changed (N = 15). The topic guide will also cover
their views on incorporating recovery interventions
within their routine clinical practice and the impact on
service users of implementing the intervention.
Interviews with service users (N = 30) Interviews will be
held midway through the trial (6 months) with service
users from the intervention teams at both sites (N = 15).
The sample will include at least five SLaM service users
from black African, black Caribbean and black Other
backgrounds. At the end of the trial (12 months), 15
participating service users (including at least five SLaM
service users from black African, black Caribbean and
black Other backgrounds) from intervention teams will
be interviewed at follow-up about their experience of tak-
ing part in the study, how the interventions were deliv-
ered in practice, and what impact the intervention has
had on their relationships with clinicians and their recov-
ery more generally.
Inerviews with trainers (N = 2) Interviews will be held
with Personal Recovery and Coaching for Recovery trai-
ners, midway through the trial (6 months).
3. Focus Groups
T e a mf o c u sg r o u p s( n=4 )At 12 months, four inter-
vention group teams will be purposively selected which
are most successful (n = 2) and least successful (n = 2)
at implementing the intervention, based on RFS-W
Table 1 Assessment measures in the REFOCUS Trial
Measure Completion time (mins) Time
Team managers
TC-F 2 B FU
All staff
SF-W 3 B FU*
RKI 5 B FU
MICA 5 B FU
RFS-W 5 B MP FU
RIS (intervention staff only) 3 FU
Paired staff - completed for each service user
HoNOS 10 B FU
CANSAS-S 10 B FU
GAF 3 B FU
Service user
SF_SU 2 B FU
NART 10 B
QPR 10 B FU
WEMWBS 5 B FU
MHCS 5 B FU
HHI 5 B FU
MANSA 10 B FU
GS-PPO 10 B FU
CSQ 5 B FU
CANSAS-SU 10 B FU
INSPIRE 10 B FU
RFS_SU 3 B FU
ICECAP-A 5 B FU
Researcher rated
BPRS 10 B FU
CSRI 10 B FU
Key:
B = Baseline
MP = Mid point 9 months after baseline, completed by team manager in intervention teams
FU = Follow up at 12 months post-baseline
* for new staff only
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identified team will be held, using a topic guide to
explore the blocks and enablers of implementation,
along with the experience of participating in the
intervention.
Service user focus groups (n = 4) At 12 months, four
focus groups will be held with service users from a high
implementation team (n = 1), low implementation team
(n = 1) and service users from black African, black Carib-
bean and black other backgrounds (n = 2). The topic
guide will explore the experience of care, and whether
any aspects have changed.
All qualitative data (staff and service user focus groups
and interviews) will be audio taped and fully transcribed.
Transcripts and notes will be read and re-read indepen-
dently by two of the research team. The data will then be
organised into initial codes and higher codes that provide
insight into emergent themes. Reliability will be enhanced
by identifying issues that are consistent between groups. A
computer software package will be used to manage the
data and increase the transparency of the analysis. Deviant
cases will be actively sought throughout the analysis and
emerging ideas and themes modified in response. Interim
analysis will identify modifications to the topic guide.
4. Training Evaluation Reports
End of training reports from Personal Recovery and
Coaching for Recovery trainers, for each of the interven-
tion teams (N = 30), specifically focussing upon the REFO-
CUS model, will be analysed qualitatively. In addition,
individual participant feedback evaluation forms on each
session of both the Personal Recovery and Coaching for
Recovery training will be analysed quantitatively.
Analysis plan
Objective 1: To establish the effectiveness of the
intervention described in the REFOCUS manual
The two trial hypotheses will be investigated using stan-
dard intention-to-treat analysis for all participants with
end-of-trial data. Firstly, to identify whether the interven-
tion was associated with improved personal recovery
(QPR) and secondly, whether it was associated with
improved secondary outcomes at the end of the interven-
tion. Individual level outcomes for staff and service users
will be aggregated at the cluster level. Analysis of covar-
iance (ANCOVA) will be used to adjust for baseline levels
including clustering effects of teams and other baseline
prognostic indicators. Sensitivity analysis will control for
baseline covariates associated with missing data. Analysis
will be blind to allocation status.
Objective 2: To validate the REFOCUS Model
The extent to which the REFOCUS Model accurately cap-
tures changes will be tested through process evaluation.
The Intervention component will be validated using data
from RFS-W and RIS, along with data about attendance at
training and reflection sessions. The practice change
component will be validated using data from MICA, RKI,
RFS-SU, RFS-W, RIS, staff focus groups and interviews,
and longitudinal routine data. The service user experience
component will be validated using data from RFS-SU,
INSPIRE, and service user focus groups and interviews.
The Outcome component will be validated using data
from the primary outcome QPR and the secondary out-
c o m e s( C S Q ,G S - P P O ,H H I ,W E M W B S ,M H C Sa n d
MANSA). In the light of this analysis, the REFOCUS
Model will be modified if necessary. A test of subgroup-
treatment effect interaction will be conducted for the
ap r i o r isub-group analysis of individals from black
backgrounds.
Objective 3: To establish and optimise trial parameters for
the REFOCUS manual
Using the elements identified in the frameworks for
optimising trial parameters [49,50], the trial analysis will
focus on the following:
Recruitment and retention
Issues arising during recruitment and factors influencing
retention will be noted, and used to inform recommenda-
tions for a recruitment and retention strategy in a future
trial. Additionally, the recruitment and retention rates will
directly inform a future sample size calculation.
Treatment fidelity
The extent to which the intervention was provided as
planned will be investigated using data from RFS-W, RIS,
the staff focus groups and semi-structured interviews, and
the longitudinal routine data. Contamination will be
assessed by comparing data from RFS-W for intervention
and control group respondents.
Implementation
Data from the RIS measure and the staff focus groups and
semi-structured interviews will be used to identify imple-
mentation components which were either highly effective
or highly burdensome. Team-level aggregated data from
the service user-level and the generic staff-level measures
will be analysed to compare the groups of the trial and,
where possible, to track longitudinal changes over time.
This will include using interrupted time series approaches
with the longitudinal routine data, to detect abrupt
changes in the time course of process indicators, and
relate them to changes in inputs.
Missing data
Sensitivity analyses will be performed to assess the influ-
ence of lost to follow-up and refusals, including imputa-
tion of missing baseline values from the within-site
means; multiple imputation of follow up values (where
feasible from other variables) and controlling for any
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the analysis.
Sample size calculation
Data from the trial will inform a sample size calculation
for a future RCT, including strengthening the robustness
of estimates of participant retention, clustering effect, and
intervention effectiveness.
Economic evaluation
The health economic component will consist of an analysis
of the cost impact of the intervention and the link between
costs and outcomes in the form of a cost-effectiveness ana-
lysis. A broad costing perspective will be used for the eco-
nomic evaluation. A societal perspective will be adopted,
thereby capturing the costs of healthcare, social care, infor-
mal care from family/friends and also lost employment.
The Client Service Receipt Inventory (CSRI) will be used
for this purpose. CSRI data will be combined with nation-
ally applicable unit costs from published sources [47]. Cost
data are usually skewed, so bootstrapping will be used to
generate confidence intervals around the cost differences.
Cost-effectiveness (C-E) will be assessed by combining the
cost and outcome data. Incremental C-E ratios will indicate
the extra cost (if any) incurred to produce an extra unit
gain in outcome. Uncertainty in the C-E estimates will be
explored using C-E planes and C-E acceptability curves.
The main outcome measures for the economic evaluation
will be those that are used for the overall evaluation. It will
also be possible to measure Quality Adjusted Life Years
(QALYs). The feasibility of this approach will be explored
further during the analysis stage.
Evaluation strategy
The comprehensive battery of assessments will allow iden-
tification of measures which provide the most useful data
for both outcome and process evaluation. Any emergent
approach to increasing blindness will be identified.
Objective 4: To understand the relationship between clinical
and recovery outcomes
The relationship between clinical outcomes (HoNOS,
CANSAS-S, CANSAS-SU, BPRS, GAF) and recovery out-
comes (QPR, HHI, MHCS) will be investigated using
multivariate modelling.
Trial Management
Dr Mike Slade (PI) will have overall responsibility for
the trial. The Trial Manager is Dr Mary Leamy (Health
Service and Population Research Department, Institute
of Psychiatry), who will be responsible for co-ordination.
Risk and adverse events
Relevant trust policies relating to potential areas of risk,
such as risk management and medication, will be adhered
t o .S e r i o u sa d v e r s ee v e n t sw i l lb em o n i t o r e db yt h eT r i a l
Manager, who will report these to the PI and where there
is a possibility that they are linked to the trial, the Trial
Steering Committee will be informed.
Trial supervision
The Trial Steering Committee will comprise four inde-
pendent members: Prof Sonia Johnson, Department of
Mental Health Sciences, University College London (chair);
Nora Donaldson, King’s College London; Pauline Edwards,
University College London; and Caroline Cuppitt, Oxleas
Mental Health NHS Trust. In addition, the Principal Inves-
tigator (Mike Slade), the site lead (Rob MacPherson) and
the Trial Manager (Mary Leamy) will attend. At the first
TSC meeting the need for a Data Monitoring and Ethics
Committee, interim analyses and stop rules for the trial
will be discussed and a Data Monitoring and Ethics Com-
m i t t e ew i l lb ec o n v e n e di fn e c e s s a r y .
The REFOCUS trial is part of the Refocus Study, which
is supported by four advisory committees [51]. The Steer-
ing group comprises co-applicants and invited experts.
The members are: Gyles Glover, Gabrielle Richards, Geoff
Shepherd, Vanessa Pinfold, Jerry Tew, Shula Ramon, Tom
Craig, Zoe Reed, Lynne Turner-Stokes, Rachel Churchill,
Graham Thornicroft, Rachel Perkins, John Larsen, Rob
Macpherson, Joanna Fox, John Weinman, Guy Saward,
Morven Leese, Paul McCrone, Tony Coggins and John
Larsen. The International Advisory Board (IAB) com-
prises: Glenn Roberts, Mark Hayward, Michael Clark,
Simon Bradstreet, Tom O’Brien, Larry Davidson, Lindsay
Oades, Marianne Farkas and Courtenay Harding. The
Lived Experience Advisory Panel (LEAP) comprises 8
people who have experience of either using mental health
services or caring for someone who has. The Black and
Minority Ethnic Virtual Consultation Panel is made up
of 12 members including researchers, clinicians and ser-
vice users either from black backgrounds or with extensive
experience of working with individuals from black back-
grounds. These have been meeting since 2009, and will
continue to meet during the trial.
Data Handling and Record Keeping
The two trial sites will enter data independently into
secure password-controlled databases held locally. Data
entry will include validation checks. Data will periodically
be merged to allow interim analysis, as requested by the
TSC and as needed by the Trial Manager to monitor pro-
gress. The only documentation which will contain identi-
fying material are the participant contact details (tear-off
portion of the SF-SU) and consent forms (containing
name). Any audiotape recordings will be destroyed once
the transcription has been checked for accuracy. All paper
forms of this data will be stored in locked filing cabinets at
each of the sites and transferred to the Institute of
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will have access to these filing cabinets. All other data will
be identified by a Participant Identification Number only.
A file linking the Participant Identification number and
personal data will be password protected and stored on a
secure server at the Institute of Psychiatry. Only the
research team will have access to this data. Electronic and
paper data will be retained for 10 years. All members of
the study team will receive MRC Good Clinical Practice
training in RCTs and we shall follow Research Governance
arrangements.
Data Access
This study will generate qualitative data comprising
interview transcripts and associated analyses, and quanti-
tative data from questionnaires. Exclusive use for primary
research by the research team is envisaged for no more
than 3 years following the study, to meet dissemination
goals. Both the quantitative and qualitative data will be
shared in anonymised form. It is anticipated that the data
may be used for secondary re-analysis as well as contri-
buting to larger datasets of routinely collected outcome
data. Archiving and curating (including data sharing
agreements and management of access rights) will be
undertaken within the framework used by King’sC o l l e g e
London, with due attention to issues of ethical (including
consent and confidentiality aspects), legal and institu-
tional regulatory permissions. Intellectual property rights
for the data will be retained by the lead applicant and
King’s College London.
Publication
The results of the research will be targeted for publica-
tion in peer-reviewed journals of general and special
interest.
Acknowledgements
This protocol presents independent research commissioned by the National
Institute for Health Research (NIHR) under its Programme Grants for Applied
Research scheme (RP-PG-0707-10040), and in relation to the NIHR Specialist
Mental Health Biomedical Research Centre at the Institute of Psychiatry,
King’s College London and the South London and Maudsley NHS
Foundation Trust. The trial has been informed by recommendations from
several advisory committees, and received support from the NIHR Mental
Health Research Network, for both of which we are grateful. The views
expressed in this publication are those of the authors and not necessarily
those of the NHS, the NIHR or the Department of Health.
Authors’ contributions
MS obtained the funding, led the study design and drafted the manuscript.
All authors contributed to the design, and read, contributed to and
approved the final manuscript.
Authors’ information
Further information about this research group is at http://
researchintorecovery.com.
Competing interests
The authors declare that they have no competing interests.
Received: 7 October 2011 Accepted: 23 November 2011
Published: 23 November 2011
References
1. National Institute for Mental Health in England: Emerging Best Practices in
Mental Health recovery London NIMHE; 2004.
2. Anthony WA: Recovery from mental illness: the guiding vision of the
mental health system in the 1990s. Innovations and Research 1993, 2: 17-24.
3. Department of Health: The Journey to Recovery - The Government’s vision for
mental health care London: Department of Health; 2001.
4. Slade M, Amering M, Oades L: Recovery: an international perspective.
Epidemiol Psichiatr Soc 2008, 17(2):128-137.
5. Care Services Improvement Partnership RCoP, Social Care Institute for
Excellence,: A common purpose: Recovery in future mental health services
Leeds CSIP; 2007.
6. Bird V, Leamy M, Le Boutillier C, Williams J, Slade M: REFOCUS: Promoting
recovery in community mental health services London: Rethink; 2011 [http://
researchintorecovery.com/refocus].
7. Slade M: Personal recovery and mental illness. A guide for mental health
professionals Cambridge: Cambridge University Press; 2009.
8. Leamy M, Bird V, Le Boutillier C, Williams J, Slade M: A conceptual
framework for personal recovery in mental health: systematic review
and narrative synthesis. Br J Psychiatry 2011, 199:445-452.
9. Green LS, Oades L, Grant AM: Cognitive-Behavioural, Solution-Focused
Life Coaching: Enhancing Goal Striving, Well-Being and Hope. Journal of
Positive Psychology 2006, 1(3):142-149.
10. Slade M: 100 ways to support recovery London: Rethink; 2009 [http://rethink.
org/100ways].
11. Woodbridge K, Fulford KWM: Whose values? A workbook for values-based
practice in mental health care London Sainsbury Centre for Mental Health;
2004.
12. Department of Health: From values to action: The chief nursing officer’s
review of mental health nursing London: HMSO; 2006.
13. Rapp C, Goscha RJ: In The Strengths Model: Case Management With People
With Psychiatric Disabilities. Volume Second.. 2 edition. New York Oxford
University Press; 2006.
14. Deegan P, Rapp C, Holter M, Riefer M: A Program to Support Shared
Decision Making in an Outpatient Psychiatric Medication Clinic. Psychiatr
Serv 2008, 59:603-605.
15. Crowe T, Deane F, Oades LG, Caputi P, Morland KG: Effectiveness of a
Collaborative Recovery Training Program in Australia in Promoting
Positive Views About Recovery. Psychiatr Serv 2006, 57(10):1497-1500.
16. Clarke SP, Oades LG, Crowe T, Deane F: Collaborative Goal Technology:
Theory and Practice. Psychiatric Rehabilitation Journal 2006, 30(2):129-136.
17. Le Boutillier C, Leamy M, Bird VJ, Davidson L, Williams J, Slade M: What
does recovery mean in practice? A qualitative analysis of international
recovery-oriented practice guidance. Psychiatr Serv 2011, 62:1470-1476.
18. Gilburt H, Slade M, Rose D, Lloyd-Evans B, Johnson S, Osborn D: Service
users’ experiences of residential alternatives to standard acute wards:
qualitative study of similarities and differences. Br J Psychiatry 2010, 197:
s26-s31.
19. Gilburt H, Rose D, Slade M: The importance of relationships in mental
health care: a qualitative study of service users’ experiences of
psychiatric hospital admission in the UK. BMC Health Services Research
2008, 8:92.
20. Brohan E, Slade M, Clement S, Thornicroft G: Experiences of mental illness
stigma, prejudice and discrimination: a review of measures. BMC Health
Services Research 2010, 10:80.
21. Slade M: Mental illness and well-being: the central importance of
positive psychology and recovery approaches. BMC Health Services
Research 2010, 10:26.
22. Drake RE, Deegan P: Are Assertive Community Treatment and Recovery
Compatible? Community Ment Health J 2008, 44:75-77.
23. Andresen R, Caputi P, Oades L: Do clinical outcome measures assess
consumer-defined recovery? Psychiatry Res 2010, 177:309-317.
24. Johnson S, Gilburt H, Lloyd-Evans B, Osborn D, Boardman J, Leese M,
Shepherd G, Thornicroft G, Slade M: Inpatient and residential alternatives
to standard acute wards in England. Br J Psychiatry 2009, , 194: 456-463.
25. Lloyd-Evans B, Slade M, Jagielska D, Johnson S: Residential alternatives to
acute psychiatric hospital admission: systematic review. Br J Psychiatry
2009, 195(2):109-117.
Slade et al. BMC Psychiatry 2011, 11:185
http://www.biomedcentral.com/1471-244X/11/185
Page 12 of 1326. Neil S, Kilbride M, Pitt L, nothard S, Welford M, Sellwood W, Morrison A: The
questionnaire about the process of recovery (QPR): A measurement tool
developed in collaboration with service users. Psychosis 2009, 1:145-155.
27. Slade M, McCrone P, Kuipers E, Leese M, Cahill S, Parabiaghi A, Priebe S,
Thornicroft G: Use of standardised outcome measures in adult mental
health services: randomised controlled trial. Br J Psychiatry 2006,
189:330-336.
28. Attkisson CC, Zwick R: The Client Satisfaction Questionnaire. Eval Program
Plann 1982, 5:233-237.
29. Osborn D, Lloyd-Evans B, Johnson S, Gilburt H, Byford S, Leese M, Slade M:
Residential alternatives to Acute Inpatient Care in England: A
comparison of satisfaction, ward atmosphere and service user
experiences. Br J Psychiatry 2010, 197:s41-s45.
30. Slade M: Routine outcome assessment in mental health services. Psychol
Med 2002, 32(8):1339-1343.
31. Slade M: What outcomes to measure in routine mental health services,
and how to assess them: a systematic review. Aust N Z J Psychiatry 2002,
36(6):743-753.
32. Medical Research Council: MRC Guidelines for Good Clinical Practice in
Clinical Trials London MRC; 1998.
33. Department of Health: Effective care co-ordination in mental health services
London: HMSO; 1999.
34. Bedregal L, O’Connell M, Davidson L: The Recovery knowledge inventory:
Assessment of mental health staff knowledge and attitudes about
recovery. Psychiatric Rehabilitation Journal 2006, 30:96-103.
35. Kassam A, Glozier N, Leese M, Thornicroft G: Development and
responsiveness of a scale to measure clinicians’ attitudes to people with
mental illness (medical student version). Acta Psychiatr Scand 2010,
122:153-161.
36. Wing JK, Beevor AS, Curtis RH, Park SB, Hadden S, Burns A: Health of the
Nation Outcome Scales (HoNOS). Research and Development. Br J
Psychiatry 1998, , 172: 11-18.
37. Slade M, Loftus L, Phelan M, Thornicroft G, Wykes T: The Camberwell
Assessment of Need London Gaskell; 1999.
38. Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, Parkinson J,
Secker J, Stewart-Brown S: The Warwick-Edinburgh Mental Well-being
Scale (WEMWBS): development and UK validation. Health and Quality of
Life Outcomes 2007, 5:63.
39. Carpinello S, Knight E, Markowitz F, Pease E: The development of the
mental health confidence scale: A measure of self-efficacy in individuals
diagnosed with mental disorders. Psychiatric Rehabilitation Journal 2000,
23:236-243.
40. Herth K: Abbreviated instrument to measure hope: development and
psychometric evaluation. J Adv Nurs 1992, 17:1251-1259.
41. Priebe S, Huxley P, Knight S, Evans S: Application and results of the
Manchester Short Assessment of quality of life. Int J Soc Psychiatry 1999, ,
45: 7-12.
42. Macpherson R, Varah M, Summerfield L, Foy C, Slade M: Staff and patient
assessments of need in an epidemiologically representative sample of
patients with psychosis. Soc Psychiatry Psychiatr Epidemiol 2003,
38(11):662-667.
43. Ruggeri M, Leese M, Slade M, Bonizzato P, Fontecedro L, Tansella M:
Demographic, clinical, social and service variables associated with
higher needs for care in community psychiatric service patients. The
South Verona Outcome Project 8. Soc Psychiatry Psychiatr Epidemiol 2004,
39(1):60-68.
44. Al-Janabi H, Flynn T, Coast J: Development of a self-report measure of
capability wellbeing for adults: the ICECAP-A. Qual Life Res 2011.
45. Nelson HE: National Adult reading Test (NART): Test Manual Windsor NFER-
Nelson; 1982.
46. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale (BPRS): Recent
Developments in Ascertainment and Scaling. Psychopharmacol Bull 1988, ,
24: 97-99.
47. Beecham J, Knapp M: Costing psychiatric interventions. In Measuring
mental health needs. Volume 2. Edited by: Thornicroft G. London: Gaskell;
2001:200-224.
48. Slade M, Luke G, Knowles L: Methodologies for evaluating recovery
training. Clinical Psychology Forum 2009, 193:10-15.
49. Lancaster GA, Dodd S, Williamson PR: Design and analysis of pilot studies:
recommendations for good practice. J Eval Clin Pract 2004, 10:307-312.
50. Campbell NC, Murray E, Darbyshire J, Emery J, Farmer A, Griffiths F,
Guthrie B, Lester H, Wilson P, Kinmonth AL: Designing and evaluating
complex interventions to improve health care. BMJ 2007, , 334: 455-459.
51. Slade M, Bird V, Chandler R, Fox J, Larsen J, Tew J, Leamy M: The
contribution of advisory committees and public involvement to large
studies: case study. BMC Health Services Research 2010, 10:323.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-244X/11/185/prepub
doi:10.1186/1471-244X-11-185
Cite this article as: Slade et al.: REFOCUS Trial: protocol for a cluster
randomised controlled trial of a pro-recovery intervention within
community based mental health teams. BMC Psychiatry 2011 11:185.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Slade et al. BMC Psychiatry 2011, 11:185
http://www.biomedcentral.com/1471-244X/11/185
Page 13 of 13